

NOTICE OF CHANGE OF LEGAL ENTITY

Date: December 28, 2016

Purpose: Legal Entity Consolidation – Letter #2

To: Suppliers of MedImmune, LLC, MedImmune Biologics, Inc. (“**MedImmune**”), and AstraZeneca LP (“**AZLP**”)

As a reminder of our initial communication sent on October 17, 2016, the non-research functions within MedImmune, LLC, MedImmune Biologics, Inc., and AstraZeneca LP will be transferred to AstraZeneca Pharmaceuticals LP (“**AZPLP**”) as of January 1, 2017 (the “**Effective Date**”). This change in legal entity structure is designed to streamline our operations. The purpose of this notice is to provide information related to this change.

We will continue to operate in the normal course of business until January 1, 2017. Beginning January 3, 2017, the affected functions of MedImmune, LLC, MedImmune Biologics, Inc., and AstraZeneca LP will begin issuing new indirect purchase orders from AstraZeneca Pharmaceuticals LP (“**AZPLP**”). Direct Material and MRO orders, (starting with 45* and 42*) will continue to be issued under the current legal entities until further notice.

The Bill-To address on our purchase orders defines the legal entity making the purchase. Please follow the instructions and submit your invoices to the appropriate address, as stated on the purchase order. As a reminder, Ariba Network invoice submission is still our preferred method of invoicing for indirect procurement. All indirect PO's can be identified as beginning with **17***, **25***, or **30*** from all North American AstraZeneca companies and group affiliates. All existing PO's created prior to January 3rd should be invoiced as per the company instructions on the original orders.

Purchase Orders issued after January 1, 2017 will continue under existing pricing and contracts, unless otherwise agreed between your company and AZPLP.

Please note that any purchase orders received from AstraZeneca Pharmaceuticals LP (“**AZPLP**”) are subject to local applicable state tax unless a tax exemption letter/certificate is otherwise provided.

Attached within this letter is a list of Frequently Asked Questions (“**FAQs**”) for your reference along with a copy of the AstraZeneca Pharmaceuticals LP W9.

As we finalize the details of this transition, we appreciate your support and patience.

If you have any questions, please contact our Purchase to Pay (“**P2P**”) Helpdesk (1-800-773-7119 or Helpdesk.USPTP@astrazeneca.com).

We look forward to a continued relationship with your company.

AstraZeneca Procurement & Finance

SUPPLIER FAQ'S

1. Who should I contact with any potential questions?

Please contact the P2P Help Desk with any questions by phone or email:

- Purchase-to-Pay Help Desk – 1-800-773-7119
- Email - Helpdesk, US PTP Helpdesk.USPTP@astrazeneca.com

The P2P Helpdesk will then direct you to the appropriate internal resources.

2. Why are we changing our legal entity structure?

We are changing the legal entity structure to streamline operations and to simplify internal processes such as ordering, contracting, and payments.

3. When will the changes occur?

Changes will commence January 1, 2017 (the “**Effective Date**”).

4. Will my open Purchase Order(s) be impacted?

In order to minimize disruption to our stakeholders and Suppliers, we will continue processing invoices against open Purchase Orders under the former legal entities through Q1 2017. Further communication will be provided at a later time regarding how open POs that extend beyond that point will be handled.

5. What is the name of the Legal Entity?

- MedImmune, LLC will continue to operate as a legal entity for purposes of Research and Development ONLY.
- MedImmune Biologics, Inc. and AstraZeneca LP will be converted into AstraZeneca Pharmaceuticals LP (“AZPLP”) and will no longer continue as legal entities. Contracts and Purchase Orders will no longer be issued under these two entities.
- The legal entity in the US, which will contain MedImmune Biologics, Inc, and AstraZeneca LP beginning January 1, 2017, will be AstraZeneca Pharmaceuticals LP (“AZPLP”).

6. Will there be changes to our daily interactions with our AstraZeneca and/or MedImmune customers?

No. Engagements and interactions with your customers will not be impacted.

7. Do I need to take any action?

Yes, the bill-to address on the purchase order defines the legal entity making the purchase. Please submit invoices as per the bill-to address instructions on each purchase order.

8. May I get a new W-9 for the AZPLP legal entity?

The W-9 for the AZPLP legal entity is attached with this Notice.

AZPLP W-9

